… We studied the PI3K inhibitor PX-866 in this single arm phase II study in recurrent GBM.
This agent was reasonably well tolerated but did not meet the predefined efficacy endpoints. …

… We present the results of PX-866, an oral PI3K inhibitor, in patients (pts) with recurrent GBM.
Methods: A multinomial design of response and early progression (< 8 weeks on study) was …

… GBM. Methods: Pts with histologically confirmed GBM at first recurrence after treatment
with … temozolomide are given PX-866 8 mg daily on this single-arm phase II study. MRI and …

… is frequently reported in primary GBM, we decided to explore … PX-866, due to its previous
use in the clinic for recurrent GBM… A phase II clinical trial was performed with PX-866 in patients …

… study by Pitz et al reports the results of a phase II study of PX-866 in patients who suffered
their first glioblastoma … conclusions from the current study with PX-866, as several important …

… PX-866 and cetuximab can be combined at the MTD of each single-agent. However, given
the small size of this study, a larger, phase 2 … multiple cycles without frequent dose reductions. …

… Discussion Our study demonstrated a modest clinical effect of PX-866 monotherapy in
men with chemotherapy-naive mCRPC with 2 partial responses and some temporary PSA …

… PX-866 is an oral, irreversible, pan-isoform inhibitor of PI3K. Preclinical … a phase 1 trial
demonstrated tolerability of this combination. This randomized phase 2 study evaluated PX-866 …

… with increased time on study in patients with … PX-866 is currently in phase II trials for
glioblastoma (NCT01259869) and CRPC (NCT01331083) and combination phase I–II studies …

… In a phase II study, 33 patients with recurrent GBM were orally administrated with PX-866.
It was relatively well-tolerated but the overall RR was low. All participants had ceased therapy …